Compare Marqeta Inc (MQ) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Novartis AG — how do they compare? Marqeta Inc trades at $15.52 (market cap $1.62B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 184.1× Marqeta Inc's market cap, and Novartis AG pays a 3.02% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| MQ | NVS | |
|---|---|---|
Market Cap | $1.62B | $298.18B |
Sector | Technology | Health |
52-Week High | $26.00 | $168.62 |
52-Week Low | $15.04 | $119.31 |
Enterprise Value | $939.53M | $339.50B |
Dividend Yield | — | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $15.96, down 4.37% on the day, with a bearish technical signal. The company reported Q2 2026 earnings with a beat on EPS and 17% net revenue growth, marking its second consecutive quarter of GAAP profitability. Recent partnerships with Google and Riskified highlight strategic expansion. However, valuation ratios remain elevated with a P/E of 177.28, and net income margin is thin at 1.53%.
The outlook is mixed; analyst consensus is a Buy with a $19.00 price target, implying upside, but execution on growth initiatives like stablecoin cards and European expansion is key. Risks include high valuation sensitivity and competitive pressures in fintech. Positive cash flow trends and recent profitability improvements provide a foundation for cautious optimism.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
